| Similar Articles |
|---|
 |
Chemistry World
July 1, 2013
Mico Tatalovic |
Croatian scientists hope to capitalize on EU membership Croatian scientists secured their first two prestigious European Research Council grants in the last eight months.   |
Chemistry World
September 4, 2013
Mico Tatalovic |
Croatian chancellors' pay slashed by 30% Croatian chancellors are now worse off. Will professors be next? |
The Motley Fool
December 30, 2008
Brian Orelli |
A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus. |
Chemistry World
March 17, 2011
Hepeng Jia |
International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation. |
Chemistry World
July 31, 2013
Andy Extance |
Pfizer reshuffle hints at future split decision Pharmaceutical giant Pfizer is internally dividing its commercial operations into three business segments, which will report profits separately from 2014 onwards. |
Chemistry World
April 24, 2007
Victoria Gill |
AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune. |
Mother Jones
Jan/Feb 2002
Bill Hogan |
A Biodefense Boondoggle As pharmaceutical companies line up for multimillion-dollar contracts to make bioterrorism vaccines, some question whether the industry is up to the job... |
Chemistry World
October 11, 2007
Hepeng Jia |
China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest. |
HBS Working Knowledge
February 28, 2005
Cynthia Churchwell |
Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution. |
HBS Working Knowledge
March 1, 2004
Martha Lagace |
Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
Chemistry World
September 26, 2007
Victoria Gill |
HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Chemistry World
March 20, 2012
Rajesh Parishwad |
India Green Lights Production of Patented Cancer Drug For the first time India has invoked a 'compulsory license' clause to cut the cost of a patented anti-cancer drug by allowing another company to manufacture the therapy. |
Pharmaceutical Executive
February 1, 2009
Patrick Clinton |
Working Together No one who cares about global health can be happy with a system that only "eventually" delivers drugs and vaccines for the planet's neediest people. |
Chemistry World
July 25, 2012 |
Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population. |
Chemistry World
February 7, 2006
Jon Evans |
Plant-Derived Drug Approved in US Dow AgroSciences has become the first biotech firm to gain US regulatory approval for a plant-derived drug. The company claims it will be able to manufacture many other vaccines, for animal and human diseases, using its plant-based production technology. |
The Motley Fool
April 4, 2006
Rich Duprey |
Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders. |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. |
The Motley Fool
June 26, 2008
Brian Lawler |
Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay. |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
Chemistry World
June 4, 2015
Phillip Broadwith |
Takeda to consolidate vaccines business in Boston Japanese pharma firm Takeda plans to close three US sites and move the headquarters of its vaccines business unit to the pharmaceutical hub in the Boston and Cambridge area of Massachusetts. |
The Motley Fool
March 7, 2011
Brian Orelli |
Kids, Vaccines, and Deaths a Bad Combination Pfizer and Sanofi may not to be to blame, but when investing in drugmakers, you always have to be worried about drug safety. Fortunately this doesn't look like one of those issues. |
Chemistry World
April 11, 2012
Mico Tatalovic |
Croatian scientists call for chemical reagent regulation Prominent Croatian scientists are calling for better regulation of the domestic market for laboratory chemicals and reagents as prices can be as much as 70% higher than in other European countries. |
Chemistry World
July 15, 2014
Emma Stoye |
Public--private research partnerships to tackle Europe's big problems The European Union will invest euro 7.3 billion in seven newly launched public -- private partnerships as part of its Horizon2020 research funding program. |
BusinessWeek
October 25, 2004
John Carey |
A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked. |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
